# Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

> **NCT02743546** · PHASE1 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Duvortuxizumab
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02743546
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07-20
- **Primary completion:** 2018-09-30
- **Final completion:** 2020-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743546, "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02743546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*